Celldex Therapeutics Inc  (CLDX) Trade Now »     Rate CLDX  -  Discuss CLDX  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

CLDX Analysis & Videos »


CLDX: Bull or Bear?

CLDX-7 Top Stocks for the World's Biggest Gathering of Cancer Docs CLDX

62%

-34.12% in 734 days http://suprastock.blogspot.com/2010/06/7-top-stocks-for-world... Celldex Therapeutics (NASDAQ: CLDX) Partnered with Pfizer, Celldex's CDX-110 was developed for glioblastoma, a common and aggressive form of brain cancer. Shares of this stock are already running nicely ahead of the ASCO meeting. Continue reading »

By  Marian Filo   (-24.55%  risk: aggressive)  06/01/10

13 comments

Dendreon’s Provenge FDA Approval Lifts Cancer Immunotherapy Stocks CLDX

73%

-46.47% in 767 days Shares of Dendreon (NASDAQ:DNDN) were  up 15% at a market cap over $6 billion before a trading halt based on news of FDA approval of its patient-derived (autologous) therapeutic cancer vaccine (active immunotherapy) PROVENGE (sipuleucel-T) for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC) patients.This is the first FDA approval for this new class of therapeutics, which is designed to stimulate a patient's own immune system to attack cancer cells in a targeted manner with less harsh side effects (flu-like sym<><><><><><><><><>... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  04/29/10

37 comments

FDA, Clinical Trial News: ASCO 2010 Preview CLDX

73%

+29.19% in 23 days (closed on 04/29/10) With the 2010 American Society of Clinical Oncology (ASCO) annual meeting quickly approaching (June 4-8 in Chicago), below is a preview of some small and micro-cap bio-pharmaceutical companies scheduled to present key clinical data and updates for a variety of anti-cancer agents in mid to late-stage clinical development. <font> Celldex Therapeutics (NASDAQ:CLDX) $6.03, market cap = $191 million </font> <font> CDX-110, EGFRvIII therapeutic cancer vaccine - brain cancer (GBM), partnered with Pfizer (NYSE:PFE) </font> <> <font> CDX-011, a monoclonal antibody-drug conjugate (ADC)... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  04/06/10

60 comments

Immune-Based Treatments for Brain Cancer Post Impressive Early-Stage Results CLDX

73%

-2.27% in 3 days (closed on 04/06/10) According to NCI/NIH statistics <font> , approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year (with a similar number estimated to occur in Europe) with Temodar (temozolomide or TMZ) given to nearly every patient with a diagnosis of GBM, which is the most common and aggressive form of primary brain cancer. Newly diagnosed individuals with GBM typically undergo surgery to remove the tumor, followed by radiation (RT) and chemotherapy (TMZ). </font> <> <font> In May 2009, Roche (OTC:RHHBY) announced that the FDA granted accelerated approval (based on ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  04/03/10

38 comments

Mentor Capital / QI, Cancer Vaccine Investing Update Report CLDX

73%

+39.91% in 101 days (closed on 04/03/10) The <font> BioMedReports.com stock research download section </font> has been updated today to reflect my new 22-page PDF report and overview of Mentor Capital (OTC: MNTR.PK), Quantum Immunologics (QI) (privately held), and clinical / regulatory updates for several other companies in the cancer vaccine that are outlined below and summarized in the report.   <> Mentor Capital is a public-traded, private equity firm that specializes in acquisitions. The Company provides passive equity funding and liquidity to smaller companies and owners by investing in select shelf IPOs, publ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  12/23/09

51 comments

Celldex Therapeutics (NASDAQ: CLDX): Plenty of Cash and Pending Clinical Catalysts CLDX

73%

-13.19% in 64 days (closed on 12/23/09) <> <> At the beginning of the month, Celldex Therapeutics (NASDAQ: CLDX) announced the successful completion of its acquisition of CuraGen (formerly CRGN), which strengthens the balance sheet (approx. $85 million in cash / equivalents) while <font> expanding the pipeline </font> and increasing the expected news flow of clinical data catalysts for the combined entity over the near to intermediate term. At the end of 2Q09, Celldex reported cash / equivalents of $31.6 million, working capital of $20.7 million, and used $13.5 million in cash to fund operations in the first six months of the ... Continue reading »

By  Mike Havrilla   (+1.04%  risk: moderate)  10/20/09

116 comments

People Bullish on CLDX

Marian Filo Principal 62% over 2 years ago	Mike Havrilla Principal 73% over 2 years ago	hackjack@126.com Analyst N/A over 2 years ago
supratrader Principal N/A over 2 years ago

People Bearish on CLDX

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.